ABSTRACT
Aims Randomized controlled trials (RCTs) have high internal validity but often have limited generalizability. To our knowledge, there are no studies examining potential differences between RCTs and real-world data in patient characteristics and risk of major adverse cardiovascular events (MACE) among patients with type 2 diabetes mellitus (T2DM) treated with long-acting insulin analogues.
Methods We emulated the DEVOTE trial of insulin degludec vs glargine among patients with T2DM using data from the United Kingdom’s Clinical Practice Research Datalink. DEVOTE eligible and ineligible subpopulations were created. Cox proportional hazards models with inverse probability of treatment weighting were used to estimate hazard ratios (HRs) and corresponding confidence intervals (CIs) for MACE comparing new users of insulin degludec to new users of insulin glargine overall and in the eligible/ineligible subpopulations.
Results There were 10,430 patients in the overall population, 5,280 in the DEVOTE eligible population, and 5,150 in the DEVOTE ineligible population. The overall (HR: 1.36, 95% CI: 0.83, 1.86) and DEVOTE eligible populations (HR: 1.07, 95% CI: 0.63, 1.58) were compatible with findings from the DEVOTE trial (HR: 0.91, 95% CI: 0.78, 1.06) for the risk of MACE. Due to a low number of events the DEVOTE ineligible population had deviations in point estimates and wider CIs (HR: 2.19, 95% CI: 0.30, 3.83).
Conclusion The risk of MACE among patients with T2DM newly prescribed insulin degludec compared to insulin glargine was consistent between the overall population and the DEVOTE eligible subpopulation, while the DEVOTE ineligible population had discrepant point estimates.
Twitter Summary Our study emulated the DEVOTE trial using RWD. Half of the RWD population would be eligible for the trial. RWD and RCTs had compatible effect estimate for risk of major cardiovascular outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
KBF is supported by a William Dawson Scholar award from McGill University. WW is supported by a McGill Internal Studentship Award and a CANadian Consortium of Clinical Trial TRAINing platform (CANTRAIN) studentship; CANTRAIN is funded by the Canadian Institutes of Health Research
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol of this study (19_217) was approved by the CPRD's Independent Scientific Advisory Committee (ISAC) and by the CIUSSS West-Central Montreal Research Ethics Board (Montreal, Canada).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
